Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha lactalbumin oleic acid - Hamlet Pharma

Drug Profile

Alpha lactalbumin oleic acid - Hamlet Pharma

Alternative Names: Alpha 1H; HAMLET; Human alpha-lactalbumin made lethal to tumours

Latest Information Update: 02 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hamlet Pharma AB
  • Developer Hamlet Pharma AB; Neurochase
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Bladder cancer
  • Preclinical Brain cancer
  • No development reported Cancer; Colorectal cancer; Glioblastoma; Papilloma; Skin cancer

Most Recent Events

  • 29 Jan 2024 Adverse events and efficacy data from a phase I/II trial in Bladder cancer released by Hamlet Pharma
  • 30 Nov 2023 Alpha lactalbumin oleic acid receives fast track status for Bladder cancer in USA
  • 28 Aug 2023 No recent reports of development identified for preclinical development in Skin-cancer in Sweden
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top